DOCSLIB.ORG

Diffuse Large B-Cell Lymphoma: New Targets and Novel Therapies Bruce D

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Diffuse Large B-Cell Lymphoma: New Targets and Novel Therapies Bruce D Cheson et al. Blood Cancer Journal (2021) 11:68 https://doi.org/10.1038/s41408-021-00456-w Blood Cancer Journal REVIEW ARTICLE Open Access Diffuse large B-cell lymphoma: new targets and novel therapies Bruce D. Cheson 1, Grzegorz Nowakowski 2 and Gilles Salles3 Abstract Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexor, and tafasitamab plus lenalidomide. Three CAR-T cell products are currently approved by the FDA, with others in clinical trials. Additional agents in development include bispecific antibodies and antibody drug conjugates. Combinations of targeted therapies should lead to further improvement in the outcome of patients with B-cell malignancies. Introduction drug conjugate polatuzumab vedotin (Pola) with bend- The non-Hodgkin lymphomas (NHL) are a diverse amustine and rituximab (Pola-BR)4; the oral nuclear group of malignancies about 80% of which are of B-cell transport (XPO1) inhibitor selinexor5; and, most recently origin (B-NHL). B-NHL vary in their presentation, clinical the combination of the anti-CD19 monoclonal antibody features, prognosis, and response to treatment. The most tafasitamab with the immunomodulatory agent lenalido- common histologic subtype is diffuse large B-cell lym- mide6. In addition are the first two CART-cell products 7 8 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; phoma (DLBCL) accounting for about a third of cases in axicabtagene ciloleucel and tisagenlecleucel . Other the United States, followed by follicular lymphoma which drugs in development that target CD20 include the bis- represents about a quarter1. The other histologies are pecific T-cell engagers (e.g., mosunetuzumab9, glofita- much less common. About 60% of DLBCL are cured with mab10, epcoritamab11, and odronextamab12). Each of regimens such as rituximab, cyclophosphamide, Adria- these has exhibited promising early data, including in mycin, vincristine, and prednisone (R-CHOP)2. However, patients who have progressed following CAR-T therapy12. most patients who relapse following or are refractory to Polatuzumab vedotin is an antibody-drug conjugate that initial therapy succumb to their disease3. New drug targets CD79b and delivers the microtubule inhibitor development over the past decade has appropriately monomethyl auristatin E (MMAE). Polatuzumab vedotin ignored cytotoxic chemotherapy drugs and focused on was studied in a phase I, dose escalation trial in 95 patients agents that target the cell surface, internal pathways, and with NHL or CLL13. The primary endpoints were to the microenvironment. The chimeric anti-CD20 mono- determine the safety and tolerability, the maximum tol- clonal rituximab revolutionized the therapy of B-NHL, erated dose (MTD), and the recommended phase II dose. prolonging survival in most subtypes. However, resistance In the lymphoma patients, the MTD was 2.4 mg/kg as a eventually develops and other strategies directed at other single agent and in combination with rituximab. Grade 3-4 targets are needed. adverse events were reported in 58% of patients, most Recently, several innovative treatments have been commonly neutropenia (40%), with peripheral sensory approved by the FDA including the anti-CD79b antibody neuropathy in 9%. Responses were reported in 54.8% of the NHL patients. The drug was too toxic and had limited activity to be further pursued in CLL. Pola-BR received Correspondence: Bruce D. Cheson ([email protected]) accelerated approval for R/R DLBCL after two prior regi- 1Lymphoma Research Foundation, New York, NY, USA 2Mayo Clinic Foundation, Rochester, MN, USA mens (one prior in the European Union) on the basis of a Full list of author information is available at the end of the article © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a linktotheCreativeCommons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Blood Cancer Journal Cheson et al. Blood Cancer Journal (2021) 11:68 Page 2 of 10 Table 1 Tafasitamab monotherapy vs L-mind regimen in NHL. Number of Overall Complete Median PFS Median DOR Reference patients response rate response rate (months) (months) Tafasitamab single agent 35 (DLBCL) 26% 6% 2.7 20.1 Jurczak22 34 (FL) 29% 9% 8.8 Not reached Lenalidomide 76 (FL) 34.2% 13.2% 4.0 6.6 Nowakowski25 single agent Tafasitamab and 81 (DLBCL) 60% 42.5% 12.1 21.7 Salles6 lenalidomide DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma, PFS progression-free survival, DOR duration of response. randomized trial comparing Pola-BR with BR, with 40 subsequent analysis including 134 patients, those <65 patients per arm in which Pola-BR achieved a higher years had an ORR of 36.5 vs 24.4% for the older patients, complete remission (CR) rate (40.0 vs 17.5%, p < .026) and CRs 17.3 and 11%, and median duration of response a longer progression-free survival (PFS) (9.5 months vs (DOR) of 9.7 and 9.2 months, respectively. 3.7 months (p = .001) and overall survival (OS) (12.4 vs There have been concerns of a potential favorable 4.7 months, p = .002). (Table 1) However, Pola-BR was selection bias in the SADAL trial in that patients could associated with more grade 3-4 neutropenia, anemia, and not have had primary refractory disease, and those with a thrombocytopenia as well as grade 1–2 peripheral previous CR or partial remission (PR) to their prior line of neuropathy4. therapy were required to wait 60 days from that treatment Selinexor is an inhibitor of exportin 1 (XPO1), the to initiate selinexor, and 98 days for those with refractory major nuclear export protein for a number of tumor disease15. The actual time from progression of disease to suppressor genes and proto-oncogenes. Elevated XPO1 selinexor therapy was 1.5 months and 3.3 months, expression inactivates tumor suppressor proteins by respectively. However, patients in the SADAL study were mislocalization. Selinexor is a specific inhibitor of XPO1, comparable to typical patients given the patient age, it reactivates tumor suppressor proteins and blocks proto- amount of prior therapy. Moreover, 30% had progressed oncogene translation, DNA damage repair. The initial after an autologous stem cell transplant and 72% were phase I trial included 79 patients with NHL, 43 of which refractory to their immediately prior treatment regimen. had relapse or refractory DLBCL14. The most common In addition, the median time from disease progression adverse events included thrombocytopenia in 47%, neu- from the last prior therapy was 59 days in the selinexor tropenia in 32% and fatigue in 11%, with hyponatremia in responders compared with 52 days in the non-responders, 10%. In DLBCL, the ORR was 32% with CR in 10% and demonstrating that response did not correlate with time mDOR of 12.8 months. Activity was also noted in small since last therapy. numbers of patients with follicular lymphoma, CLL, Richter transformation, mantle cell and T-cell lympho- Targeting CD19 mas. The recommended phase 2 dose was 60 mg orally Another potential target is the CD19 antigen. CD19 is a twice weekly. Selinexor received accelerated approval for 95 kd, type I, transmembane glycoprotein. Expression of R/R or transformed DLBCL following two prior regimens CD19 is specific to B-lymphocytes and follicular dendritic on the basis of the SADAL single arm trial in patients with cells on which it is ubiquitous. Expression of CD19 on de novo or transformed DLBCL not considered eligible cells of B-lineage can be through the various stages of for autologous stem cell transplantation (ASCT) or post- differentiation from pre-B cells until plasma cells. CD19 ASCT5. These 134 patients had a median age of 67 years, functions as a positive regulator of B-cell receptor (BCR) median of two prior regimens, with 53% progressing signaling and is critical for B-cell development, and, in within a year of their first therapy for DLBCL. This oral mice the ability to mount an immune response to mito- agent achieved an ORR of 28% including 13% CRs and gens, and the production of serum immunoglobulins16. with a median duration of response of 9.3 months, but CD19 is present on malignant cells from the majority of was 23 months for the CRs. At the 60 mg twice weekly patients with NHL, acute lymphoblastic leukemia (ALL) dose used in this study, and with intensive anti-emetic and chronic lymphocytic leukemia (CLL). While CD20 support, the drug was well tolerated. The most common has a higher average density of surface molecules per toxicity was fatigue in 63%, which was grade 3 or 4 in 15%. tumor cell, CD19 expression is more homogenous and is Other grade 3–4 toxicities were uncommon. In a preserved in small CD20-negative tumor subsets and after Blood Cancer Journal Cheson et al. Blood Cancer Journal (2021) 11:68 Page 3 of 10 Fig. 1 Mechanism of action of tafasitamab and lenalidomide. Tafasitamab has been Fc enhanced to increase antibody-dependent cellular cytotoxicity (ADCC) which augments interactions with natural killer (NK) cells activated and expanded by lenalidomide, antibody-dependent cellular phagocytosis (ADCP) to enhance interactions with macrophages, and direct cell death.
Load more

Recommended publications
  • Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
    Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami) Media Release Copenhagen, Denmark and Lausanne, Switzerland, October 30, 2020 • ADC Therapeutics to continue the development and commercialization of Cami • Genmab to receive mid-to-high single-digit tiered royalty Genmab A/S (Nasdaq: GMAB) and ADC Therapeutics SA (NYSE: ADCT) today announced that they have executed an amended agreement for ADC Therapeutics to continue the development and commercialization of camidanlumab tesirine (Cami). The parties first entered into a collaboration and license agreement in June 2013 for the development of Cami, an antibody drug conjugate (ADC) which combines Genmab’s HuMax®-TAC antibody targeting CD25 with ADC Therapeutics’ highly potent pyrrolobenzodiazepine (PBD) warhead technology. Under the terms of the 2013 agreement, the parties were to determine the path forward for continued development and commercialization of Cami upon completion of a Phase 1a/b clinical trial. ADC Therapeutics previously announced that Cami achieved an overall response rate of 86.5%, including a complete response rate of 48.6%, in Hodgkin lymphoma patients in this trial who had received a median of five prior lines of therapy. Cami is currently being evaluated in a 100-patient pivotal Phase 2 clinical trial intended to support the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). The trial is more than 50 percent enrolled and ADC Therapeutics anticipates reporting interim results in the first half of 2021. “We have a long-standing relationship with the ADC Therapeutics team and believe they are an ideal partner for the ongoing development and potential commercialization of Cami,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
    [Show full text]
  • Draft Minutes PDCO 12-15 November 2019
    11 December 2019 EMA/PDCO/615413/2019 Inspections, Human Medicines Pharmacovigilance and Committees Division Paediatric Committee (PDCO) Minutes for the meeting on 12-15 November 2019 Chair: Koenraad Norga – Vice-Chair: Sabine Scherer Health and safety information In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting. Disclaimers Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued). Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes. Further information with relevant explanatory notes can be found at the end of this document. Note on access to documents Some documents mentioned in these minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
    [Show full text]
  • Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma
    Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma Yuliya Linhares1, Mitul Gandhi2, Michael Chung3, Jennifer Adeleye4, David Ungar4, Mehdi Hamadani5 1Medical Oncology, Miami Cancer Institute, Baptist Health, Miami, FL, USA; 2Medical Oncology, Virginia Cancer Specialists, Gainesville, VA, USA; 3Hematology/Oncology, The Oncology Institute of Hope and Innovation, Downey, CA, USA; 4Clinical Development, ADC Therapeutics America, Inc., Murray Hill, NJ, USA; 5Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA Poster slides, 62nd ASH Annual Meeting and Poster session II, Sunday, December 6, 2020: Exposition, Virtual Meeting, December 5–8, 2020 7:00 am – 3:30 pm (Pacific Time) Introduction The prognosis of patients with DLBCL whose disease is refractory to initial chemotherapy (and are thus ineligible for ASCT) or relapse early after ASCT is extremely poor1,2 The development of a more effective, less toxic salvage treatment for DLBCL remains an unmet need2 Loncastuximab tesirine (Lonca) is an ADC comprising a Mechanism of action of Lonca humanized monoclonal anti-CD19 antibody conjugated to a pyrrolobenzodiazepine (PBD) dimer toxin, through a protease cleavable valine–alanine linker Rituximab is an anti-CD20 monoclonal antibody used as a standard component of care for the treatment of DLBCL, either as monotherapy or in combination with chemotherapy In a Phase 2 study, Lonca demonstrated single-agent antitumor activity with manageable toxicity in patients with R/R DLBCL3 Rituximab is licensed for treatment of NHL but is being used in combination with an unlicensed drug (loncastuximab tesirine) in this study 1. Crump M, et al.
    [Show full text]
  • Antibody–Drug Conjugates
    Published OnlineFirst April 12, 2019; DOI: 10.1158/1078-0432.CCR-19-0272 Review Clinical Cancer Research Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index Steven Coats1, Marna Williams1, Benjamin Kebble1, Rakesh Dixit1, Leo Tseng1, Nai-Shun Yao1, David A. Tice1, and Jean-Charles Soria1,2 Abstract Since the first approval of gemtuzumab ozogamicin nism of activity of the cytotoxic warhead. However, the (Mylotarg; Pfizer; CD33 targeted), two additional antibody– enthusiasm to develop ADCs has not been dampened; drug conjugates (ADC), brentuximab vedotin (Adcetris; Seat- approximately 80 ADCs are in clinical development in tle Genetics, Inc.; CD30 targeted) and inotuzumab ozogami- nearly 600 clinical trials, and 2 to 3 novel ADCs are likely cin (Besponsa; Pfizer; CD22 targeted), have been approved for to be approved within the next few years. While the hematologic cancers and 1 ADC, trastuzumab emtansine promise of a more targeted chemotherapy with less tox- (Kadcyla; Genentech; HER2 targeted), has been approved to icity has not yet been realized with ADCs, improvements treat breast cancer. Despite a clear clinical benefit being dem- in technology combined with a wealth of clinical data are onstrated for all 4 approved ADCs, the toxicity profiles are helping to shape the future development of ADCs. In this comparable with those of standard-of-care chemotherapeu- review, we discuss the clinical and translational strategies tics, with dose-limiting toxicities associated with the mecha- associated with improving the therapeutic index for ADCs. Introduction in antibody, linker, and warhead technologies in significant depth (2, 3, 8, 9). Antibody–drug conjugates (ADC) were initially designed to leverage the exquisite specificity of antibodies to deliver targeted potent chemotherapeutic agents with the intention of improving Overview of ADCs in Clinical Development the therapeutic index (the ratio between the toxic dose and the Four ADCs have been approved over the last 20 years (Fig.
    [Show full text]
  • Full Prescribing Information [FDA]
    HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------------CONTRAINDICATIONS------------------------------ These highlights do not include all the information needed to use None. MONJUVI safely and effectively. See full prescribing information for MONJUVI. ------------------------WARNINGS AND PRECAUTIONS----------------------- Infusion-Related Reactions: Monitor patients frequently during infusion. MONJUVI® (tafasitamab-cxix) for injection, for intravenous use Interrupt or discontinue infusion based on severity. (2.3, 5.1) Initial U.S. Approval: 2020 Myelosuppression: Monitor complete blood counts. Manage using dose modifications and growth factor support. Interrupt or discontinue -----------------------------INDICATIONS AND USAGE-------------------------- MONJUVI based on severity. (2.3, 5.2) MONJUVI is a CD19-directed cytolytic antibody indicated in combination Infections: Bacterial, fungal and viral infections can occur during and with lenalidomide for the treatment of adult patients with relapsed or following MONJUVI. Monitor patients for infections. (2.3, 5.3) refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, Embryo-Fetal Toxicity: May cause fetal harm. Advise females of including DLBCL arising from low grade lymphoma, and who are not eligible reproductive potential of the potential risk to a fetus and use of effective for autologous stem cell transplant (ASCT). contraception. (5.4) This indication is approved under accelerated approval based on overall -------------------------------ADVERSE
    [Show full text]
  • Antibody–Drug Conjugates: the Last Decade
    pharmaceuticals Review Antibody–Drug Conjugates: The Last Decade Nicolas Joubert 1,* , Alain Beck 2 , Charles Dumontet 3,4 and Caroline Denevault-Sabourin 1 1 GICC EA7501, Equipe IMT, Université de Tours, UFR des Sciences Pharmaceutiques, 31 Avenue Monge, 37200 Tours, France; [email protected] 2 Institut de Recherche Pierre Fabre, Centre d’Immunologie Pierre Fabre, 5 Avenue Napoléon III, 74160 Saint Julien en Genevois, France; [email protected] 3 Cancer Research Center of Lyon (CRCL), INSERM, 1052/CNRS 5286/UCBL, 69000 Lyon, France; [email protected] 4 Hospices Civils de Lyon, 69000 Lyon, France * Correspondence: [email protected] Received: 17 August 2020; Accepted: 10 September 2020; Published: 14 September 2020 Abstract: An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylotarg®) was used clinically, in 2020, 9 Food and Drug Administration (FDA)-approved ADCs are available, and more than 80 others are in active clinical studies. This review will focus on FDA-approved and late-stage ADCs, their limitations including their toxicity and associated resistance mechanisms, as well as new emerging strategies to address these issues and attempt to widen their therapeutic window. Finally, we will discuss their combination with conventional chemotherapy or checkpoint inhibitors, and their design for applications beyond oncology, to make ADCs the magic bullet that Paul Ehrlich dreamed of. Keywords: antibody–drug conjugate; ADC; bioconjugation; linker; payload; cancer; resistance; combination therapies 1.
    [Show full text]
  • 5.01.582 Antibody-Drug Conjugates
    MEDICAL POLICY – 5.01.582 Antibody-Drug Conjugates Effective Date: June 1, 2021 RELATED MEDICAL POLICIES: Last Revised: May 11, 2021 None Replaces: N/A Select a hyperlink below to be directed to that section. POLICY CRITERIA | CODING | RELATED INFORMATION EVIDENCE REVIEW | REFERENCES | HISTORY ∞ Clicking this icon returns you to the hyperlinks menu above. Introduction An antibody is a blood protein. When the immune system detects an unhealthy cell, antibodies link to a molecule, known as an antigen, on the unhealthy cell. Monoclonal antibodies are produced in a laboratory. They are made to link to antigens usually found in high numbers on cancer cells. Antibody-drug conjugates combine monoclonal antibodies with certain chemotherapy drugs. The monoclonal antibodies find the cancer cells and the chemotherapy drug is released directly into those cells. The goal with this treatment is to target only cancer cells and spare nearby healthy cells. This policy describes when specific antibody-drug conjugates may be considered medically necessary. Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered. Policy Coverage Criteria Drug Medical
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • Corporate Medical Policy Tafasitamab-Cxix (Monjuvi®)
    Corporate Medical Policy Tafasitamab-cxix (Monjuvi®) File Name: tafasitamab_monjuvi Origination: 10/2020 Last CAP Review: 1/2021 Next CAP Review: 1/2022 Last Review: 1/2021 Description of Procedure or Service Tafasitamab-cxix (Monjuvi®) is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). DLBCL is the most common subtype of non-Hodgkin lymphoma (NHL), representing approximately one-third of NHL patients. It is an aggressive and quickly progressing NHL in which survival without treatment is measured in months. While there have been many advancements in the treatment of DLBCL, a cure is not achieved in most patients using conventional therapy, and roughly 30 to 40% of patients suffer relapse. For patients who are refractory to initial treatment and for patients who relapse after an initial response, only a small percentage will experience prolonged disease-free survival with salvage chemoimmunotherapy treatment alone. The preferred treatment for a first relapse of DLBCL or primary refractory DLBCL is salvage chemoimmunotherapy followed by autologous hematopoietic stem cell transplantation (HSCT). However, the outcome for relapsed/refractory DLBCL patients who are ineligible for transplant remains poor. Tafasitamab-cxix (Monjuvi) is a humanized CD19-directed cytolytic monoclonal antibody, which was approved by the U.S. Food and Drug Administration (FDA) in July 2020 for the treatment of relapsed or refractory DLBCL. It works by binding to CD19 expressed on the surface of pre-B and mature B lymphocytes and on several B-cell malignancies, including DLBCL, which induces B-cell lysis via apoptosis and immune effector mechanisms.
    [Show full text]
  • Antibodies for the Treatment of Brain Metastases, a Dream Or a Reality?
    pharmaceutics Review Antibodies for the Treatment of Brain Metastases, a Dream or a Reality? Marco Cavaco, Diana Gaspar, Miguel ARB Castanho * and Vera Neves * Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal * Correspondence: [email protected] (M.A.R.B.C.); [email protected] (V.N.) Received: 19 November 2019; Accepted: 28 December 2019; Published: 13 January 2020 Abstract: The incidence of brain metastases (BM) in cancer patients is increasing. After diagnosis, overall survival (OS) is poor, elicited by the lack of an effective treatment. Monoclonal antibody (mAb)-based therapy has achieved remarkable success in treating both hematologic and non-central-nervous system (CNS) tumors due to their inherent targeting specificity. However, the use of mAbs in the treatment of CNS tumors is restricted by the blood–brain barrier (BBB) that hinders the delivery of either small-molecules drugs (sMDs) or therapeutic proteins (TPs). To overcome this limitation, active research is focused on the development of strategies to deliver TPs and increase their concentration in the brain. Yet, their molecular weight and hydrophilic nature turn this task into a challenge. The use of BBB peptide shuttles is an elegant strategy. They explore either receptor-mediated transcytosis (RMT) or adsorptive-mediated transcytosis (AMT) to cross the BBB. The latter is preferable since it avoids enzymatic degradation, receptor saturation, and competition with natural receptor substrates, which reduces adverse events. Therefore, the combination of mAbs properties (e.g., selectivity and long half-life) with BBB peptide shuttles (e.g., BBB translocation and delivery into the brain) turns the therapeutic conjugate in a valid approach to safely overcome the BBB and efficiently eliminate metastatic brain cells.
    [Show full text]
  • Loncastuximab Tesirine-Lpyl
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZYNLONTA safely and effectively. See full prescribing information for ZYNLONTA. ZYNLONTA™ (loncastuximab tesirine-lpyl) for injection, for ------------------------WARNINGS AND PRECAUTIONS----------------------- intravenous use Effusion and Edema: Monitor for the development of pleural effusion, Initial U.S. Approval: 2021 pericardial effusion, ascites, peripheral edema, and general edema. Consider diagnostic imaging when symptoms develop or worsen. (5.1) -----------------------------INDICATIONS AND USAGE-------------------------- Myelosuppression: Monitor blood cell counts. Withhold, reduce, or ZYNLONTA is a CD19-directed antibody and alkylating agent conjugate discontinue ZYNLONTA based on severity. (5.2) indicated for the treatment of adult patients with relapsed or refractory large Infections: Monitor for infection and treat promptly. (5.3) B-cell lymphoma after two or more lines of systemic therapy, including Cutaneous Reactions: Monitor patients for new or worsening cutaneous diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL reactions, including photosensitivity reactions. Dermatologic consultation arising from low grade lymphoma, and high-grade B-cell lymphoma. (1) should be considered. (5.4) Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of the This indication is approved under accelerated approval based on overall potential risk to a fetus and to use effective contraception. (5.5, 8.1, 8.3)
    [Show full text]
  • Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma Brad S
    Published OnlineFirst November 4, 2019; DOI: 10.1158/1078-0432.CCR-19-0711 Clinical Trials: Targeted Therapy Clinical Cancer Research A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma Brad S. Kahl1, Mehdi Hamadani2, John Radford3, Carmelo Carlo-Stella4, Paolo Caimi5, Erin Reid6, Jay M. Feingold7, Kirit M. Ardeshna8, Melhem Solh9, Leonard T. Heffner10, David Ungar7, Shui He7, Joseph Boni7, Karin Havenith11, and Owen A. O'Connor12 Abstract Purpose: ADCT-402 (loncastuximab tesirine) is an anti- 200 mg/kg. Treatment-emergent adverse events (TEAEs) were body–drug conjugate comprising a CD19-targeting antibody experienced by 87/88 (98.9%) patients. Most common TEAEs and pyrrolobenzodiazepine dimers. A first-in-human study (20% of patients) were hematologic abnormalities, fatigue, evaluated the safety and preliminary clinical activity of lon- edema, liver test abnormalities, nausea, rash, and dyspnea. castuximab tesirine in patients with B-cell non-Hodgkin lym- Grade 3 TEAEs (5% of patients) included hematologic phoma (NHL). abnormalities, liver test abnormalities, fatigue, and dyspnea. Experimental Design: A multicenter, phase I, dose- Overall response rate at doses 120 mg/kg was 59.4% (41 of 69 escalation and dose-expansion study enrolled patients ages patients; 40.6% complete response; 18.8% partial response). 18 years with relapsed/refractory (R/R) B-cell NHL. Patients Median duration of response, progression-free survival, and received loncastuximab tesirine every 3 weeks at doses overall survival (all doses) were 4.8, 5.5, and 11.6 months, assigned by a 3þ3 dose-escalation design.
    [Show full text]